Abstract
This phase I study was aimed to assess the safety and efficacy of concurrent selective lymph node (SLN) late course accelerated hyper-fractionated (LCAF) intensity modulated radiotherapy (IMRT) and S-1, Cisplatin (CDDP) for the locally advanced esophageal squamous cell carcinoma (ESCC). The total dose of SLN LCAF IMRT was 59.6Gy/34 fractions in 5.4 weeks. The concurrent chemotherapy was administrated as following: CDDP 25mg/m2 on days 1–3 and 22–24, S-1 was applied in a de-escalating dosage with a decrement of 10 mg/m2/day, from its full dose level of 80 mg/m2, orally twice daily on days 1-14 and 22-35. We inferred the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs) and recommended dose according to adverse reaction during concurrent chemo-radiotherapy (CCRT). Total 15 ESCC patients with T2-4N0-1M0-1a were enrolled into dose level 1 (80 mg/m2). In the initial 5 patients, 2 patients developed DLTs. As MTD not reached, 5 additional patients were treated with the same dose level and DLTs only occurred in one patient. The similar results were found in the last 5 patients. After CCRT, the objective response rates were 100% for primary tumors and 86.2% for metastatic lymph nodes, respectively. Totally, the observed Grade 3 toxicities during CCRT were leucopenia (20%), neutropenia (20%) and dermatitis (13.3%), and no Grade 4 toxicity occurred. The Kaplan–Meier estimated overall and progression survival rates were 86.7% and 66.7% (1-year), 73.3% and 60% (2-year), 73.3% and 60% (3-year). The concurrent SLN LCAF IMRT and chemotherapy with S-1 and CDDP was well tolerated and performed a promising efficacy. The dose of S-1 in this regimen was recommended with 80 mg/m2 orally twice daily on days 1-14, 22-35. Concurrent chemoradiotherapy with S-1 plus cisplatin exhibited encouraging results with milder toxicities, high objective response rates and ideal overall survival time.

This publication has 31 references indexed in Scilit: